Injective Launches Pre-IPO Market for Anthropic Ahead of Nasdaq Listing

Injective is testing whether tokenized pre-IPO exposure can serve as a crypto-native on-ramp to private AI equity, a niche that sits at the intersection of two of the market's strongest narratives. The absence of listing date or pricing details means the market is effectively trading on sentiment rather than any disclosed valuation anchor, which is where the real risk sits. It matters most for RWA and DeFi venues competing for access products, and for Anthropic-adjacent exposure seekers who otherwise lack a route. The open question is whether demand holds once concrete IPO terms emerge.